Chinesestuff

From SusoSight
Jump to: navigation, search


   * Pinnacle Partners
   * EB-5 / Regional Center
   * IP / Technology Transfer
   * Tech Investment Fund
   * Products
   * Contact Us

Home Products PDF Print E-mail

这些独特的技术产品,

即拥有完整的知识产权保护,又有生产厂家的支持服务。我们为您提供中英文版本的介绍草案,中文部分请向下拖拉。


Technology licensing and IP rights Transfer Offer

The offer of these exclusive technology products featuring complete I.P. protection and producer support, are offered in English and Chinese. For Chinese please scroll down the page.


外携式可调节药物剂量治疗仪

美国设计专利获得批准,美国食品和药物管理局批准进入销售和市场营销,目前主要销售对象为在美国本土开业的医生


概述

本公司开发及销售为管理术后疼痛,提供局部治疗的一次性医疗设备产品。公司的镇痛泵与局部麻醉剂结合,使用在手术以后减少或消灭对全身麻醉剂的需要。本产品可以预先设定进入人体的药物剂量。


本产品可以让医生在为患者治疗术后疼痛时,采用身体局部麻醉靶向特定部位。这种治疗方案,更好地控制了疼痛,加快恢复,改善患者术后情况,减少病人住院时间和住院费用。


本系统减少了因使用麻醉而产生的严重副作用,包括恶心、肠梗阻(“肠冻结综合症”)、精神错乱。在门诊手术中使用这些镇痛泵,可增加患者周转率,医生的工作安排极其方便,显著地增加了业务量和收入。


产品

ext1

本产品是一种一次性人造橡胶机械泵,装置内注入局部麻醉剂,与外科医生和麻醉师提供的控制药物一并使用。将该设备连接到一个导管,放置在手术切口或接近手术切口的地方,控制流入导管的局部麻醉剂量。手术后,患者可佩带此设备,回家家可移除或丢弃。本设备和局部麻醉剂有效地控制了患者的疼痛感,并且减少甚至消除患者对全身麻醉的需要。



产品成本仅为医用PCA(患者控制麻醉)泵的一小部分。相比较与清洁和保养患者间使用的PCA,本产品花费要低廉的多。更重要的是,采用这种治疗形式,患者可以随时回家,不同于花费高昂的PCA系统。


产品的关键指标:

成本节省优秀

+ 比当前的PCA技术便宜

+ 减少了清洁PCA设备的花费

+ 一次性使用,每位患者使用后即丢弃

+ 全面改善了患者满意度

+ 在相同产品中,最佳的安全外形

+ 可治疗更广泛的患者群


提升黄金标准

+ 患者可将此一体化的系统带回家使用

+ 普通常见和使用方法和流程,医生通过极简单的培训即可使用

+ 让患者可以尽早下床活动,提高产量,使病患尽快出院,从而大大增加了病患的周转率,同时降低整体去医院的花费


ext2


大事记

+ 公司已有属于第二类医疗器械产品510K的第一代产品生产线

+ 公司将于2011年,为此第二类医疗器械产品510K,申请第二代产品。此开发过程将严格遵循美国FDA最新颁发的输液泵指南

+ 公司成功通过了美国FDA2009年度的生产流程检查


实用性:

+ 领先的专利医疗设备的直接投资机会

+ 即刻获取技术的权利

+ 合作生产权



Investor Return

As the Company continues to grow, it will become an attractive acquisition opportunity for a variety of potential suitors. These could include medical device companies, medical product distributors or private equity groups.


The Company believes that it will be a successful investment because:

+ It can capture a significant market share

+ Strategic partnership will drive adoption domestically AND internationally

+ The Company will exit at attractive multiples

+ An exit could occur within a few years ext3


如您对上述任何一个方案感兴趣,请按以下方式联系我们:


尖峰技术股份有限公司

沃尔那特北大街520号

印弟安那州布卢明顿市

邮编:47404


请洽:谢凯文 先生 / Kevin Jeffers

中国资产管理部 副总裁

电话:(812) 606-1550

传真:(812) 335-1961


信箱地址:

印弟安那州布卢明顿市

1772信箱

邮编:47402

________________________________________________________________________________


Technology licensing and IP rights Transfer Offer

The offer of these exclusive technology products featuring complete I.P. protection and producer support, are offered in English and Chinese. For Chinese please scroll down the page.


External medication device with flow regulator

U.S. Design Patent approved, U.S.A. Food and Drug Administration approved for sales and marketing, now sold to doctors practicing in the U.S.


Overview

The Company develops and sells disposable medical device products that provide localized treatment for post-operative pain management. The Company’s pump devices are used in conjunction with local anesthetics to reduce or eliminate the need for systemic narcotics after surgery. The product is preset for controlled medication distribution.


The product allows the physician to treat post-operative pain by targeting specific areas of the body using local anesthetics. This type of treatment gives better pain control, faster recoveries, improved patient outcomes and reduces extended patient stay and hospital costs.


The system reduces the serious side-effects related to narcotic use including nausea, ileus (“frozen bowel syndrome”), mental confusion. Using these types of pumps in an ambulatory surgery center environment increases patient turn-over and positively impacts physician scheduling and significantly increases throughput and revenue.


The Product

ext1

The product is a disposable elastomeric, mechanical pump devices filled with a local anesthetic and with controlled medication delivery by surgeons and anesthesiologists. The device is attached to a catheter that is placed into or near the surgical incision and it controls the flow of the local anesthetic into the catheter. The patient wears the filled device after surgery and takes it home with them where it can be removed and disposed. The device and the local anesthetic control the patient’s pain effectively and it reduces or eliminates the need for the patient to take systemic narcotics.


Product cost is a fraction of hospital based PCA (Patient Controlled Anesthesia) pumps. The product also costs less than to clean and maintain a PCA pump between patient use. Most importantly this treatment modality can be taken home, unlike higher cost PCA systems.



Brief key product points:

Superior Cost Savings

+ Less expensive than current PCA technology

+ Reduces cost to clean PCA units

+ One time use and disposable for each patient

+ Overall improvement of patient satisfaction

+ Best safety profile for equivalent units

+ Able to treat a wider patient population


Enhancement to the Gold Standard

+ All-in-one system can be taken home by the patient

+ Minimal physician training required – common practice and procedure

+ Allows for earlier time to ambulation, increased throughput and faster discharge from the hospital,

resulting in higher patient turnover and a lower overall cost to the hospital

ext2

Regulatory Milestones

+ The Company has an existing Class II 510k for its first generation product line.

+ The Company will be applying for a Class II 510k on its second generation device in 2011. The development process is strictly adhering to the recently FDA issued Infusion Pump Guidelines.

+ The Company successfully passed a 2009 FDA inspection of its manufacturing operations.


Availability:

+ Immediate investment opportunity in this leading FDA approved medical device company

+ Immediate access to Generation 1 technology

+ Co-operative production rights


Investor Return

As the Company continues to grow, it will become an attractive acquisition opportunity for a variety of potential suitors. These could include medical device companies, medical product distributors or private equity groups.


The Company believes that it will be a successful investment because:

+ It can capture a significant market share

+ Strategic partnership will drive adoption domestically AND internationally

+ The Company will exit at attractive multiples

+ An exit could occur within a few years ext3


If you are interested in one of these product offerings, contact us at the following address:


Pinnacle Technology LLC

520 North Walnut Street

Bloomington Indiana 47404


Attention: Kevin Jeffers

Vice President Asset Management / China

Phone number: (812) 606-1550

Fax number: (812) 335-1961


Mailing address:

P.O. Box 1772

Bloomington, In 47402

Pinnacle International LLC., Powered by Forte Web Works, LLC Valid XHTML and CSS.